Wasatch Advisors’s Aquestive Therapeutics AQST Stock Holding History

Wasatch Advisors’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.77M	Buy	1,385,843 +507,527	+58%	+$2.14M	0.04%	170
2026 Q1	$3.65M	Buy	878,316 +197,076	+29%	+$800K	0.02%	180
2025 Q4	$4.4M	Sell	681,240 -43,038	-6%	-$268K	0.03%	180
2025 Q3	$4.05M	Buy	+724,278	New	+$3.13M	0.02%	196
2019 Q1	–	Sell	-145,373	Closed	-$916K	–	224
2018 Q4	$916K	Hold	145,373	–	–	0.01%	223
2018 Q3	$2.54M	Buy	+145,373	New	+$2.4M	0.03%	215

Other funds holding AQST

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

SMAM

Sugar Maple Asset Management Sister Bay, Wisconsin $155M AUM 17.72% 1-Year Est. Return

Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

SWRP

Summit Wealth & Retirement Planning San Ramon, California $472M AUM 25.49% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $43.3B AUM 29.3% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return

Wasatch Advisors's AQST Position: Q2 2026 in Review

Wasatch Advisors increased its Aquestive Therapeutics (AQST) stake by 58% in Q2 2026, buying an estimated $2.14M and bringing the position to 1,385,843 shares worth $5.77M. The position accounts for 0.04% of the portfolio, ranked #170.

Wasatch Advisors first reported a position in AQST in Q3 2018 and has held it in 6 quarters since. 32 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

Wasatch Advisors held 1,385,843 shares of Aquestive Therapeutics worth $5.77M as of Q2 2026.
Wasatch Advisors bought 507,527 Aquestive Therapeutics shares in Q2 2026, an estimated $2.14M.
Aquestive Therapeutics made up 0.04% of Wasatch Advisors's portfolio in Q2 2026, its #170 holding.
Wasatch Advisors first reported a position in Aquestive Therapeutics in Q3 2018 and has held it in 6 quarters since.
32 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Wasatch Advisors's 13F filing for Q2 2026, filed 10 Jul 2026.